Identification, assessment and management of breast oedema after treatment for cancer.

Int J Palliat Nurs

Lymphoedema Clinical Nurse Specialist, LySpecialist Lymphoedema Service, Glasgow, NHS Greater Glasgow & Clyde.

Published: September 2017

Advances in breast cancer management, including breast-conserving surgery, have resulted in an increase in the incidence of breast oedema. However, this is addressed by professionals less often than arm lymphoedema. Breast oedema results in significant physical and psychological morbidity, makes finding a comfortably fitting bra very difficult, and can act as a reminder of the initial breast cancer diagnosis. Psychological difficulties can be compounded by clinicians' failure to acknowledge the impact. Assessing and managing breast oedema requires a sensitive, skilled approach to ensure all the relevant issues are identified and addressed in a comprehensive care plan; taking time to listen to patients and acknowledging the impact can be very therapeutic. The principles of managing breast oedema are based on lymphoedema practice, particularly manual lymphatic drainage and kinesio taping. This article gives an overview of the identification, assessment and management of breast oedema following treatment of cancer.

Download full-text PDF

Source
http://dx.doi.org/10.12968/ijpn.2017.23.9.440DOI Listing

Publication Analysis

Top Keywords

breast oedema
24
identification assessment
8
assessment management
8
breast
8
management breast
8
oedema treatment
8
treatment cancer
8
breast cancer
8
managing breast
8
oedema
6

Similar Publications

Identifying phase-separated structures remains challenging, and effective intervention methods are currently lacking. Here we screened for phase-separated proteins in breast tumour cells and identified forkhead (FKH) box protein M1 (FOXM1) as the most prominent candidate. Oncogenic FOXM1 underwent liquid-liquid phase separation (LLPS) with FKH consensus DNA element, and compartmentalized the transcription apparatus in the nucleus, thereby sustaining chromatin accessibility and super-enhancer landscapes crucial for tumour metastatic outgrowth.

View Article and Find Full Text PDF

Objective: This retrospective study aimed to evaluate the predictive value of the preoperative dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) and diffusion-weighted imaging (DWI) findings of mass lesions for predicting sentinel lymph node (SLN) metastasis in early breast cancer.

Methods: A total of 310 patients with suspicious mass lesions detected in preoperative MRI who subsequently underwent surgery and SLN biopsy (SLNB) between September 2015 and September 2022 were analyzed. The relationship between DCE-MRI and DWI findings and SLNB positivity was analyzed.

View Article and Find Full Text PDF

Purpose: Trastuzumab-pertuzumab (HP) plus taxane is a current standard first-line therapy for recurrent or metastatic human epidermal growth factor 2 (HER2)+ breast cancer (BC). We investigated noninferiority of eribulin to a taxane when combined with dual HER2 blockade as first-line systemic treatment for locally advanced/metastatic HER2+ BC.

Methods: In the phase III EMERALD trial (target sample size, 480; ClinicalTrials.

View Article and Find Full Text PDF

Intensity-modulated radiation therapy for early-stage breast cancer: a systematic review and meta-analysis.

Sao Paulo Med J

January 2025

Professor, Discipline of Evidence-Based Medicine, Escola Paulista de Medicina (EPM), Universidade Federal de São Paulo (Unifesp), São Paulo, SP, Brazil; Consultant, Centre of Health Technology Assessment, Hospital Sírio-Libanês, São Paulo (SP), Brazil.

Background: Radiation therapy (RT) is a standard treatment for non-metastatic breast cancer and is associated with acute and late toxicities. Intensity-modulated RT (IMRT) may decrease toxicity and is convenient for patients.

Objectives: To assess the efficacy and safety of IMRT in women with early stage breast cancer.

View Article and Find Full Text PDF

Tamoxifen, an oral medication that blocks estrogen activity, is frequently prescribed for the treatment of advanced breast cancer and as an additional therapy following surgical removal of early stage disease. A 45-year-old female with a history of breast carcinoma treated with tamoxifen presented with sudden onset bilateral visual impairment for 4 days. On ocular examination, the patient exhibited optic disc edema with hyperemia and bilateral anterior pathway defects in visual evoked potentials.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!